Monitoring Desk
NEW YORK: Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop the first antiviral pill for COVID-19.
Pfizer said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.
The trial would test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Merck and partner Ridgeback Biotherapeutics said earlier this month they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection.
Pfizer had also said earlier this month it started a mid-to-late-stage trial of PF-07321332 for the treatment of COVID-19 in non-hospitalized, symptomatic adult patients.
Courtesy: (Newsmax)
Jalil Afridi On June 25, 2024, the U.S. House of Representatives passed House Resolution 901…
BERLIN (AFP): Marcel Sabitzer lashed home to earn Austria a thrilling 3-2 win against the…
ST LUCIA (Agencies): David Warner's international cricket career is over after Australia were eliminated from…
Dr. Abdel Aziz Aluwaisheg Hungary will next week assume the rotating EU presidency, to the…
HAN ZHAOYING and LIU JIN The United States House Foreign Affairs Committee overwhelmingly passed the…
This website uses cookies.